IS7328A - Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum - Google Patents

Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum

Info

Publication number: IS7328A
Authority: IS; Iceland
Prior art keywords: aerokinases; inhibit; replaced; quinazoline derivatives; quinazoline
Prior art date: 2001-12-24

Application number

IS7328A

Other languages

English (en)

Other versions

IS2758B (is

Inventor

Henri Jung Frederic

Rene Pasquet Georges

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-24

Filing date

2004-06-21

Publication date

2004-06-21

2004-06-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2004-06-21 Publication of IS7328A publication Critical patent/IS7328A/is

2011-10-15 Publication of IS2758B publication Critical patent/IS2758B/is

Links

125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IS7328A 2001-12-24 2004-06-21 Setnar kínasólínafleiður sem hemlar gegn Áróra kínösum IS2758B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01403357		2001-12-24
PCT/GB2002/005845 WO2003055491A1 (en)	2001-12-24	2002-12-20	Substituted quinazoline derivatives as inhibitors of aurora kinases

Publications (2)

Publication Number	Publication Date
IS7328A true IS7328A (is)	2004-06-21
IS2758B IS2758B (is)	2011-10-15

Family

ID=8183051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7328A IS2758B (is)	2001-12-24	2004-06-21	Setnar kínasólínafleiður sem hemlar gegn Áróra kínösum

Country Status (31)

Country	Link
US (2)	US7402585B2 (is)
EP (1)	EP1463506B1 (is)
JP (1)	JP4498741B2 (is)
KR (1)	KR101029281B1 (is)
CN (1)	CN100491372C (is)
AR (1)	AR038052A1 (is)
AT (1)	ATE446093T1 (is)
AU (1)	AU2002353196B2 (is)
BR (1)	BRPI0215312B8 (is)
CA (1)	CA2471577C (is)
CY (1)	CY1109681T1 (is)
DE (1)	DE60234125D1 (is)
DK (1)	DK1463506T3 (is)
ES (1)	ES2333702T3 (is)
HU (1)	HU229477B1 (is)
IL (1)	IL162541A0 (is)
IS (1)	IS2758B (is)
MX (1)	MXPA04006260A (is)
MY (1)	MY141739A (is)
NO (1)	NO328159B1 (is)
NZ (1)	NZ533440A (is)
PL (1)	PL211694B1 (is)
PT (1)	PT1463506E (is)
RU (1)	RU2323215C2 (is)
SA (1)	SA03230531B1 (is)
SI (1)	SI1463506T1 (is)
TW (1)	TWI335818B (is)
UA (1)	UA82058C2 (is)
UY (1)	UY27604A1 (is)
WO (1)	WO2003055491A1 (is)
ZA (1)	ZA200404923B (is)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60144284D1 (de)	2000-11-01	2011-05-05	Millennium Pharm Inc	Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
ES2333702T3 (es) *	2001-12-24	2010-02-26	Astrazeneca Ab	Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
EP2280003B1 (en)	2002-07-15	2014-04-02	Symphony Evolution, Inc.	Process for preparing receptor-type kinase modulators
PT1847539E (pt) *	2002-12-24	2009-10-06	Astrazeneca Ab	Derivados de quinazolina
WO2004094410A1 (en)	2003-04-16	2004-11-04	Astrazeneca Ab	Chemical compounds
US20060135541A1 (en) *	2003-06-02	2006-06-22	Astrazeneca Ab	(3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) *	2003-06-17	2005-02-16	Astrazeneca Ab	Chemical compounds
AU2003304266A1 (en) *	2003-07-03	2005-01-21	Cambridge University Technical Services Ltd	Use of aurora kinase inhibitors for reducing the resistance of cancer cells
KR101028952B1 (ko) *	2003-08-14	2011-04-12	어레이 바이오파마 인크.	수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
EP2392565B1 (en)	2003-09-26	2014-03-19	Exelixis, Inc.	c-Met modulators and methods of use
ES2344007T3 (es) *	2003-10-14	2010-08-16	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Inhibidores proteina quinasa.
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
US7572914B2 (en)	2003-12-19	2009-08-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP1763524A1 (en) *	2004-04-23	2007-03-21	Takeda San Diego, Inc.	Indole derivatives and use thereof as kinase inhibitors
NZ550796A (en)	2004-05-06	2010-07-30	Warner Lambert Co	4-phenylamino-quinazolin-6-yl-amides
DE602005024274D1 (de) *	2004-07-16	2010-12-02	Sunesis Pharmaceuticals Inc	Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
WO2006023931A2 (en) *	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
TW200624431A (en) *	2004-09-24	2006-07-16	Hoffmann La Roche	Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
AU2005293336B2 (en)	2004-10-12	2009-05-28	Astrazeneca Ab	Quinazoline derivatives
US7713973B2 (en)	2004-10-15	2010-05-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
JP2008520713A (ja)	2004-11-17	2008-06-19	ミイカナセラピューティクスインコーポレイテッド	キナーゼ阻害剤
GB0427917D0 (en) *	2004-12-21	2005-01-26	Astrazeneca Ab	Chemical compounds
WO2006118231A1 (ja)	2005-04-28	2006-11-09	Mitsubishi Tanabe Pharma Corporation	シアノピリジン誘導体及びその医薬としての用途
GB0510963D0 (en) *	2005-05-28	2005-07-06	Astrazeneca Ab	Chemical compounds
EP1915377A1 (en)	2005-07-22	2008-04-30	Sunesis Pharmaceuticals, Inc.	Pyrazolo pyrimidines useful as aurora kinase inhibitors
CA2622352C (en) *	2005-09-30	2014-05-27	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
GB0601215D0 (en) *	2006-01-21	2006-03-01	Astrazeneca Ab	Chemical compounds
EA018128B1 (ru)	2006-01-23	2013-05-30	Амген Инк.	Модуляторы аурора киназы, способы их получения и их применение
US7560551B2 (en)	2006-01-23	2009-07-14	Amgen Inc.	Aurora kinase modulators and method of use
US7868177B2 (en)	2006-02-24	2011-01-11	Amgen Inc.	Multi-cyclic compounds and method of use
EP1994024A2 (en) *	2006-03-02	2008-11-26	AstraZeneca AB	Quinoline derivatives
UY30183A1 (es) *	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
CA2645583A1 (en) *	2006-03-20	2007-09-27	F. Hoffman-La Roche Ag	Methods of inhibiting btk and syk protein kinases
JP2009530330A (ja) *	2006-03-20	2009-08-27	エフ．ホフマン−ラロシュアーゲー	フタラジノンピラゾール誘導体、その製造および医薬品としての使用
GB0609617D0 (en)	2006-05-16	2006-06-21	Astrazeneca Ab	Process & intermediate
GB0609621D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal
CA2652634A1 (en) *	2006-05-18	2007-11-29	Amphora Discovery Corporation	Certain substituted quinolones, compositions, and uses thereof
GB0619342D0 (en) *	2006-09-30	2006-11-08	Vernalis R&D Ltd	New chemical compounds
JPWO2008041767A1 (ja)	2006-10-05	2010-02-04	萬有製薬株式会社	ＡｕｒｏｒａＡ阻害剤の薬効を予測又は診断する遺伝子・タンパク質マーカー
GEP20135728B (en)	2006-10-09	2013-01-25	Takeda Pharmaceuticals Co	Kinase inhibitors
EP2223925A1 (en) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase inhibitors
MX2009010517A (es)	2007-04-05	2009-10-19	Amgen Inc	Moduladores de cinasa aurora y metodos de uso.
JP2010529193A (ja) *	2007-06-11	2010-08-26	ミイカナセラピューティクスインコーポレイテッド	置換ピラゾール化合物
AU2008273017C1 (en)	2007-06-29	2014-02-13	Millennium Pharmaceuticals, Inc.	Heterocyclic compounds useful as Raf kinase inhibitors
WO2009111028A1 (en)	2008-03-04	2009-09-11	Vitae Pharmaceuticals, Inc.	Aurora kinase inhibitors
WO2009117157A1 (en)	2008-03-20	2009-09-24	Amgen Inc.	Aurora kinase modulators and method of use
WO2010019473A1 (en)	2008-08-14	2010-02-18	Amgen Inc.	Aurora kinase modulators and methods of use
RS52754B2 (sr)	2009-01-16	2022-08-31	Exelixis Inc	Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
HRP20141239T1 (xx) *	2009-02-11	2015-03-13	Merck Patent Gmbh	Novi amino azaheterocikliäśki karboksamidi
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
EP2465842A1 (de) *	2010-12-17	2012-06-20	Sika Technology AG	Amine mit sekundären aliphatischen Aminogruppen
KR101940340B1 (ko)	2011-03-04	2019-01-18	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	키나제 억제제로서의 아미노-퀴놀린
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118652D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
AU2013205306B2 (en)	2012-03-16	2015-09-17	Axikin Pharmaceuticals, Inc.	3,5-diaminopyrazole kinase inhibitors
WO2013143466A1 (zh) *	2012-03-27	2013-10-03	广东东阳光药业有限公司	作为欧若拉激酶抑制剂的取代嘧啶衍生物
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209609D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
AR092529A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
BR112015019624A2 (pt) *	2013-02-21	2017-07-18	Glaxosmithkline Ip Dev Ltd	quinazolinas como inibidores de quinase
CN104098551B (zh) *	2013-04-03	2019-03-22	广东东阳光药业有限公司	作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
DK3046584T3 (en)	2013-09-16	2017-10-02	Astrazeneca Ab	THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN105916506B (zh)	2013-11-20	2020-01-07	圣诺康生命科学公司	作为tam家族激酶抑制剂的喹唑啉衍生物
HUE053654T2 (hu)	2014-03-26	2021-07-28	Astex Therapeutics Ltd	FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
KR102479696B1 (ko)	2014-03-26	2022-12-22	아스텍스 테라퓨틱스 리미티드	Fgfr 억제제 및 igf1r 억제제의 조합물
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CN107250116B (zh)	2014-12-23	2020-10-27	艾士盟医疗公司	3,5-二氨基吡唑激酶抑制剂
JOP20200201A1 (ar)	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
EP3353164B1 (en)	2015-09-23	2021-11-03	Janssen Pharmaceutica, N.V.	Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CA2996857C (en)	2015-09-23	2024-05-21	Janssen Pharmaceutica Nv	Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
CN112939948B (zh) *	2019-12-11	2022-05-17	苏州美诺医药科技有限公司	新型含喹唑啉类化合物及其中间体与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) *	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
AU658646B2 (en)	1991-05-10	1995-04-27	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (is)	1994-11-12	1997-12-01	Zeneca Ltd
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
DK1119567T3 (da) *	1998-10-08	2005-07-25	Astrazeneca Ab	Quinazolinderivater
GB9922171D0 (en) *	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
CN1391562A (zh)	1999-09-21	2003-01-15	阿斯特拉曾尼卡有限公司	用作药物的喹唑啉衍生物
GB0006864D0 (en) *	2000-03-21	2000-05-10	Smithkline Beecham Plc	New use
EE200200715A (et) *	2000-06-28	2004-08-16	Astrazeneca Ab	Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
US6610677B2 (en) *	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
GB0124299D0 (en) *	2001-10-10	2001-11-28	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
ES2333702T3 (es) *	2001-12-24	2010-02-26	Astrazeneca Ab	Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
US7105425B1 (en) *	2002-05-16	2006-09-12	Advanced Micro Devices, Inc.	Single electron devices formed by laser thermal annealing
PT1847539E (pt) *	2002-12-24	2009-10-06	Astrazeneca Ab	Derivados de quinazolina
WO2004094410A1 (en) *	2003-04-16	2004-11-04	Astrazeneca Ab	Chemical compounds
US20060135541A1 (en) *	2003-06-02	2006-06-22	Astrazeneca Ab	(3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
EP1802608A1 (en) *	2004-10-12	2007-07-04	AstraZeneca AB	Quinazoline derivatives for use against cancer
GB0427917D0 (en) *	2004-12-21	2005-01-26	Astrazeneca Ab	Chemical compounds
JP2008542345A (ja) *	2005-05-28	2008-11-27	アストラゼネカアクチボラグ	キナゾリン類及びオーロラキナーゼ阻害剤としてのその使用
GB0601215D0 (en) *	2006-01-21	2006-03-01	Astrazeneca Ab	Chemical compounds
GB0609619D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Combination
GB0609621D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal
GB0609617D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Process & intermediate
US20100004247A1 (en) *	2007-12-12	2010-01-07	Astrazeneca Ab	Combination comprising a mek inhibitor and an aurora kinase inhibitor 188

2002
- 2002-12-20 ES ES02788214T patent/ES2333702T3/es not_active Expired - Lifetime
- 2002-12-20 RU RU2004122926/04A patent/RU2323215C2/ru active
- 2002-12-20 DK DK02788214T patent/DK1463506T3/da active
- 2002-12-20 AT AT02788214T patent/ATE446093T1/de active
- 2002-12-20 SI SI200230864T patent/SI1463506T1/sl unknown
- 2002-12-20 CN CNB028283058A patent/CN100491372C/zh not_active Expired - Lifetime
- 2002-12-20 UA UA20040706026A patent/UA82058C2/uk unknown
- 2002-12-20 JP JP2003556068A patent/JP4498741B2/ja not_active Expired - Lifetime
- 2002-12-20 NZ NZ533440A patent/NZ533440A/en not_active IP Right Cessation
- 2002-12-20 US US10/499,684 patent/US7402585B2/en not_active Expired - Lifetime
- 2002-12-20 EP EP02788214A patent/EP1463506B1/en not_active Expired - Lifetime
- 2002-12-20 WO PCT/GB2002/005845 patent/WO2003055491A1/en not_active Ceased
- 2002-12-20 KR KR1020047010003A patent/KR101029281B1/ko not_active Expired - Lifetime
- 2002-12-20 PL PL371253A patent/PL211694B1/pl unknown
- 2002-12-20 IL IL16254102A patent/IL162541A0/xx unknown
- 2002-12-20 DE DE60234125T patent/DE60234125D1/de not_active Expired - Lifetime
- 2002-12-20 MX MXPA04006260A patent/MXPA04006260A/es active IP Right Grant
- 2002-12-20 BR BRPI0215312A patent/BRPI0215312B8/pt not_active IP Right Cessation
- 2002-12-20 AU AU2002353196A patent/AU2002353196B2/en not_active Expired
- 2002-12-20 HU HU0402454A patent/HU229477B1/hu unknown
- 2002-12-20 CA CA2471577A patent/CA2471577C/en not_active Expired - Lifetime
- 2002-12-20 PT PT02788214T patent/PT1463506E/pt unknown
- 2002-12-23 MY MYPI20024859A patent/MY141739A/en unknown
- 2002-12-23 AR ARP020105081A patent/AR038052A1/es active IP Right Grant
- 2002-12-24 TW TW091137139A patent/TWI335818B/zh not_active IP Right Cessation
- 2002-12-24 UY UY27604A patent/UY27604A1/es not_active Application Discontinuation
2003
- 2003-01-28 SA SA03230531A patent/SA03230531B1/ar unknown
2004
- 2004-06-21 IS IS7328A patent/IS2758B/is unknown
- 2004-06-22 ZA ZA2004/04923A patent/ZA200404923B/en unknown
- 2004-07-23 NO NO20043158A patent/NO328159B1/no not_active IP Right Cessation
2008
- 2008-05-28 US US12/128,479 patent/US20090215770A1/en not_active Abandoned
2009
- 2009-12-17 CY CY20091101316T patent/CY1109681T1/el unknown

Also Published As

Publication number	Publication date
US20090215770A1 (en)	2009-08-27
TWI335818B (en)	2011-01-11
CN100491372C (zh)	2009-05-27
SA03230531B1 (ar)	2008-09-08
US7402585B2 (en)	2008-07-22
JP2005525307A (ja)	2005-08-25
NO328159B1 (no)	2009-12-21
AR038052A1 (es)	2004-12-22
CA2471577A1 (en)	2003-07-10
US20050070561A1 (en)	2005-03-31
MXPA04006260A (es)	2005-03-31
IL162541A0 (en)	2005-11-20
UY27604A1 (es)	2003-07-31
BRPI0215312B1 (pt)	2018-03-27
DE60234125D1 (de)	2009-12-03
PL371253A1 (en)	2005-06-13
HU229477B1 (en)	2014-01-28
PT1463506E (pt)	2009-12-10
TW200410697A (en)	2004-07-01
HUP0402454A3 (en)	2009-08-28
IS2758B (is)	2011-10-15
AU2002353196A1 (en)	2003-07-15
AU2002353196B2 (en)	2008-01-17
CN1620296A (zh)	2005-05-25
PL211694B1 (pl)	2012-06-29
MY141739A (en)	2010-06-15
SA03230531A (ar)	2005-12-03
ES2333702T3 (es)	2010-02-26
ZA200404923B (en)	2005-11-30
WO2003055491A1 (en)	2003-07-10
RU2004122926A (ru)	2005-07-10
UA82058C2 (uk)	2008-03-11
EP1463506A1 (en)	2004-10-06
JP4498741B2 (ja)	2010-07-07
HUP0402454A2 (hu)	2005-03-29
EP1463506B1 (en)	2009-10-21
BR0215312A (pt)	2004-12-07
KR20040066929A (ko)	2004-07-27
SI1463506T1 (sl)	2010-01-29
DK1463506T3 (da)	2010-01-11
NZ533440A (en)	2006-08-31
KR101029281B1 (ko)	2011-04-18
CY1109681T1 (el)	2014-08-13
CA2471577C (en)	2011-08-02
RU2323215C2 (ru)	2008-04-27
HK1076598A1 (zh)	2006-01-20
ATE446093T1 (de)	2009-11-15
NO20043158L (no)	2004-09-16
BRPI0215312B8 (pt)	2021-05-25

Publication	Publication Date	Title
IS7328A (is)	2004-06-21	Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum
IS7240A (is)	2004-04-30	Kínasólínafleiður sem æxliseyðandi efni
IS7241A (is)	2004-04-30	Kínasólínafleiður sem æxliseyðandi efni
IS6886A (is)	2003-07-24	Kínasólín sem MMP-13 hindrar
IS7362A (is)	2004-07-22	Kínasólín efnasambönd
DK1847539T3 (da)	2009-11-09	Quinazolin-derivater
DK1671949T3 (da)	2008-11-03	Substituerede pyridinylaminer
IS6298A (is)	2002-03-13	Teridínón sem tálmar kínasa
IS7884A (is)	2005-06-09	Díasepínóindól afleiður sem kínasa hindrar
IS6971A (is)	2003-09-29	Ný efnasambönd
ATE319451T1 (de)	2006-03-15	Tetrahydrochinolin-derivate
ATE312827T1 (de)	2005-12-15	3-substituierte-4-pyrimidonderivate
DE50206892D1 (de)	2006-06-29	Substituierte imidazotriazinone
NO20035573L (no)	2004-02-16	Kinazolinderivater
DK1373228T3 (da)	2008-08-04	Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE60231830D1 (de)	2009-05-14	Verriegelungsanordnung
DE60239393D1 (de)	2011-04-21	Verriegelungsanordnung
DE50202174D1 (de)	2005-03-10	Schliesszylinder
DE60223031D1 (de)	2007-11-29	Arylpiperazin gebundene tetrahydroindolonderivate
DK1406858T3 (da)	2009-11-23	Substituerede 4-aminocyklohexanoler
DE60203764D1 (de)	2005-05-25	Flachprofil-Wegwerfpolymerkapillarkissen
DE60202381D1 (de)	2005-01-27	Paroxetin-n-formyl-derivate
DE60216967D1 (de)	2007-02-01	Substituierte cyclohexanderivate
FI4977U1 (fi)	2001-06-27	Lukituslaite
SE0100694D0 (sv)	2001-02-28	DHFR inhibitors